viewAllergy Therapeutics PLC

Allergy Therapeutics reports positive results from early-stage study of dust mite jab

Not only was Acarovac seen to be safe and well-tolerated in the phase I trial, but the 16 patients taking part also enjoyed a “significant improvement” in their symptoms

dust mite
Allergy was spun out of SmithKline Beecham (now GSK) back in 1999

Allergy Therapeutics PLC (LON:AGY) has reported positive results from the early-stage study of Acarovac – its dust mite allergy jab.

The drug was tested in 16 patients as part of the phase I trial to assess its safety and tolerability.

Sufferers were given seven injections over a 6-12 week period.

READ: Allergy thinks its adjuvant system could be used in fight against cancer

Allergy said Acarovac was well tolerated and had a satisfactory safety profile, with reported adverse events similar to what has been observed with similar vaccines.

In addition to those primary endpoints, researchers also found that the injection had a “significant improvement” on patients’ total symptom scores.

“The success of our clinical trial in house dust mite-induced allergic rhinitis is encouraging news for the many patients who continue to suffer with the symptoms caused by house dust mite allergy, and supports our ambition to provide a global therapy for the important US, China and EU markets,” said chief executive Manuel Llobet.

“Based on the unique triple-combination of our allergoids, and the adjuvant system MPL and MCT we believe Acarovac MPL could build on our success in dust mite immunotherapy and we look forward to progressing towards phase II clinical studies.”

In a note to clients, analysts at ‘house broker’ finnCap commented: “This study will allow the company to proceed with a larger Phase II dose ranging study, which we expect to begin in late 2019/2020. We make no change to forecasts and reiterate our target price of 40p.”

In afternoon trading, shares in Allergy Therapeutics were changing hands at 12.50p each.

 -- Adds analyst comment, share price --

Quick facts: Allergy Therapeutics PLC

Price: 16.5 GBX

Market: AIM
Market Cap: £105.58 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...


Market report: Weaker pound steers FTSE higher, while Tesla drives investors...

The FTSE is higher this Wednesday. One of the main talking points today - is Tesla (NASDAQ: TSLA) after much anticipation leading up to CEO Elon Musk’s announcement - it failed to impress - slashing $50 billion from Tesla's market value after a promise to cut electric vehicle costs so...

on 23/9/20

2 min read